Michel Heaulme

TL;DR: SR141716A is the first selective and orally active antagonist of the brain cannabinoid receptor and should prove to be a powerful tool for investigating the in vivo functions of the anandamide/cannabinoid system.

TL;DR: Being a potent and selective neurotensin receptor antagonist, SR 48692 may be considered as a powerful tool for investigating the role of neurotens in physiological and pathological processes.

TL;DR: SR140333 potently, selectively and competitively inhibited substance P binding to NK1 receptors from various animal species, including humans, and exerted highly potent antagonism towardNK1 receptors in vitro and in vivo.

TL;DR: In vitro, SR141716A antagonizes the inhibitory effects of cannabinoid receptor agonists on both mouse vas deferens contractions and dopamine-stimulated adenylyl cyclase activities in rat brain membranes, and will provide a powerful tool for studying the in vivo functions of the anandamide/cannabinoid system.

TL;DR: SSR504734 is a potent and selective GlyT1 inhibitor, exhibiting activity in schizophrenia, anxiety and depression models, and is expected to be efficacious not only against positive but also negative symptoms, cognitive deficits, and comorbid depression/anxiety states.